Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Reig Jofré Group in connection with the business acquisition of Bioglan AB
Mandate

Vinge advises Reig Jofré Group in connection with the business acquisition of Bioglan AB

September 07, 2009

Vinge has advised Reig Jofré Group in connection with the acquisition of the business of Bioglan AB from Midelfart Sonesson. Reig Joflé Group is one of the leading companies in Spain within the pharmaceuticals industry. Bioglan AB conducts operations in relation to contract development and manufacture of dermatological pharmaceuticals under the supervision of the Swedish Medical Products Agency.

Reig Jofré Group was advised by partner Peter Abrahamsson and associates Kristian Ford, Andreas Schöldström, Marcus Bergdahl, Anna Bjering and Anna Bergstrand.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026